Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- s13058-023-01673-w
Final published version, 897 KB, PDF document
Introduction: Height, body mass index (BMI), and weight gain are associated with breast cancer risk in the general population. It is unclear whether these associations also exist for carriers of pathogenic variants in the BRCA1 or BRCA2 genes. Patients and methods: An international pooled cohort of 8091 BRCA1/2 variant carriers was used for retrospective and prospective analyses separately for premenopausal and postmenopausal women. Cox regression was used to estimate breast cancer risk associations with height, BMI, and weight change. Results: In the retrospective analysis, taller height was associated with risk of premenopausal breast cancer for BRCA2 variant carriers (HR 1.20 per 10 cm increase, 95% CI 1.04–1.38). Higher young-adult BMI was associated with lower premenopausal breast cancer risk for both BRCA1 (HR 0.75 per 5 kg/m2, 95% CI 0.66–0.84) and BRCA2 (HR 0.76, 95% CI 0.65–0.89) variant carriers in the retrospective analysis, with consistent, though not statistically significant, findings from the prospective analysis. In the prospective analysis, higher BMI and adult weight gain were associated with higher postmenopausal breast cancer risk for BRCA1 carriers (HR 1.20 per 5 kg/m2, 95% CI 1.02–1.42; and HR 1.10 per 5 kg weight gain, 95% CI 1.01–1.19, respectively). Conclusion: Anthropometric measures are associated with breast cancer risk for BRCA1 and BRCA2 variant carriers, with relative risk estimates that are generally consistent with those for women from the general population.
| Original language | English |
|---|---|
| Article number | 72 |
| Journal | Breast Cancer Research |
| Volume | 25 |
| Issue number | 1 |
| Number of pages | 13 |
| ISSN | 1465-5411 |
| DOIs | |
| Publication status | Published - Dec 2023 |
Bibliographical note
Funding Information:
The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Netherlands Cancer Institute (coordinating center), Amsterdam, NL: M.K. Schmidt, F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, D.J. Stommel-Jenner, R. de Groot, L. Hordijk; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, I. Geurts-Giele, M.J. Hooning, I.A. Boere; Leiden University Medical Center, NL: C.J. van Asperen, P. Devilee, R.B. van der Luijt, T.C.T.E.F. van Cronenburg; Radboud University Medical Center Nijmegen, NL: M.R. Wevers, A.R. Mensenkamp; University Medical Center Utrecht, NL: M.G.E.M. Ausems, M.J.
Funding Information:
Open Access funding enabled and organized by Projekt DEAL. The HEBON study is supported by the Dutch Cancer Society Grants NKI1998-1854, NKI2004-3088, NKI2007-3756, NKI 12535, the Netherlands Organisation of Scientific Research Grant NWO 91109024, the Pink Ribbon Grants 110005 and 2014-187.WO76, the BBMRI Grant NWO 184.021.007/CP46, and the Transcan Grant JTC 2012 Cancer 12-054. The EMBRACE study is supported by Cancer Research- UK Grants: PRCPJT-Nov21\100004, C1287/A23382 and C1287/A26886. MT is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014 and NIHR203312). DGE was supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The national French cohort, GENEPSO, had been supported by a grant from the Fondation de France, the Ligue Nationale Contre le Cancer, by a grant from INCa as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, no. 2014-008) and is being supported by Institut National du Cancer-DGOS, Grant PRT-K22-076 and by the “Programmes labellisés (PGA) 2022” of the Fondation ARC (N°ARCPGA2022010004414_4863). The Breast Cancer Family Registry (BCFR) is supported by Grant U01 CA164920 from the USA National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. A.O. is partially funded by FIS PI19/00640 supported by FEDER funds and the Spanish Network on Rare Diseases (CIBERER). The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and the kConFab Follow-Up Study have been supported by grants from Cancer Australia (809195 and 1100868), the Australian National Breast Cancer Foundation (IF 17 kConFab), the National Health and Medical Research Council (454508, 288704, and 145684), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. K-AP is a National Health and Medical Research Council Leadership Fellow (Australia) (1195294). The GC-HBOC is supported by the German Cancer Aid (Grant No. 110837 and Grant No. 70114178, coordinator: Rita K. Schmutzler, Cologne) and the Federal Ministry of Education and Research (BMBF), Germany (Grant No. 01GY1901). Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCAs) was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program and by the Canadian Breast Cancer Research Alliance-Grant #019511. LF and DB supported by MH CZ-DRO (MMCI, 00209805). Role of the funders: The funding organizations had no role in the design and conduct of the study.
Publisher Copyright:
© 2023, The Author(s).
ID: 373037250